Novacyt: Lyn Rees, James MacCarthy, Joanne Mason, Andrew Heath

Lyn Rees has been appointed as CEO of molecular diagnostics firm Novacyt, effective May 1, replacing James McCarthy, who has been acting CEO. McCarthy will remain with the company for an unspecified period of time to ensure a smooth transition, Novacyt said.

Rees was most recently CEO of Yourgene Health, which was acquired by Novacyt last year. Before that, he was Group CEO at British Biocell International.

In addition, Novacyt's CSO Joanne Mason will join the company's board as an executive director, also effective May 1, pending shareholder approval, while Andrew Health will retire as non-executive director. Mason was previously CSO of Yourgene Health. Before that, she held scientific roles at Cambridge Epigenetix, Genomics England, and the Oxford Biomedical Research Centre. She holds a PhD in molecular and cellular biology from the University of Cambridge.